148 related articles for article (PubMed ID: 36706959)
21. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - Radiological features and metric markers.
Le Fèvre C; Constans JM; Chambrelant I; Antoni D; Bund C; Leroy-Freschini B; Schott R; Cebula H; Noël G
Crit Rev Oncol Hematol; 2021 Mar; 159():103230. PubMed ID: 33515701
[TBL] [Abstract][Full Text] [Related]
22. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis.
Song YS; Choi SH; Park CK; Yi KS; Lee WJ; Yun TJ; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Jahng GH; Chang KH
Korean J Radiol; 2013; 14(4):662-72. PubMed ID: 23901325
[TBL] [Abstract][Full Text] [Related]
23. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging.
Zeng QS; Li CF; Liu H; Zhen JH; Feng DC
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):151-8. PubMed ID: 17289287
[TBL] [Abstract][Full Text] [Related]
24. Vascular architecture mapping for early detection of glioblastoma recurrence.
Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S
Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560
[TBL] [Abstract][Full Text] [Related]
25. Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Ratai EM; Zhang Z; Snyder BS; Boxerman JL; Safriel Y; McKinstry RC; Bokstein F; Gilbert MR; Sorensen AG; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):936-44. PubMed ID: 23645534
[TBL] [Abstract][Full Text] [Related]
26. Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.
Wang S; Martinez-Lage M; Sakai Y; Chawla S; Kim SG; Alonso-Basanta M; Lustig RA; Brem S; Mohan S; Wolf RL; Desai A; Poptani H
AJNR Am J Neuroradiol; 2016 Jan; 37(1):28-36. PubMed ID: 26450533
[TBL] [Abstract][Full Text] [Related]
27. Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy.
Stadlbauer A; Pichler P; Karl M; Brandner S; Lerch C; Renner B; Heinz G
Eur J Radiol; 2015 Jun; 84(6):1128-36. PubMed ID: 25795194
[TBL] [Abstract][Full Text] [Related]
28. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
[TBL] [Abstract][Full Text] [Related]
29. Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation.
Hagiwara A; Schlossman J; Shabani S; Raymond C; Tatekawa H; Abrey LE; Garcia J; Chinot O; Saran F; Nishikawa R; Henriksson R; Mason WP; Wick W; Cloughesy TF; Ellingson BM
J Neurooncol; 2022 Sep; 159(3):509-518. PubMed ID: 35842871
[TBL] [Abstract][Full Text] [Related]
30. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review: Part 1 - Molecular, morphological and clinical features.
Le Fèvre C; Lhermitte B; Ahle G; Chambrelant I; Cebula H; Antoni D; Keller A; Schott R; Thiery A; Constans JM; Noël G
Crit Rev Oncol Hematol; 2021 Jan; 157():103188. PubMed ID: 33307200
[TBL] [Abstract][Full Text] [Related]
31. Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
Khalifa J; Tensaouti F; Lotterie JA; Catalaa I; Chaltiel L; Benouaich-Amiel A; Gomez-Roca C; Noël G; Truc G; Péran P; Berry I; Sunyach MP; Charissoux M; Johnson C; Cohen-Jonathan Moyal E; Laprie A
J Neurooncol; 2016 Oct; 130(1):181-192. PubMed ID: 27502603
[TBL] [Abstract][Full Text] [Related]
32. Distinction between glioma progression and post-radiation change by combined physiologic MR imaging.
Matsusue E; Fink JR; Rockhill JK; Ogawa T; Maravilla KR
Neuroradiology; 2010 Apr; 52(4):297-306. PubMed ID: 19834699
[TBL] [Abstract][Full Text] [Related]
33. Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review.
Sidibe I; Tensaouti F; Roques M; Cohen-Jonathan-Moyal E; Laprie A
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203493
[TBL] [Abstract][Full Text] [Related]
34. Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation.
Qian X; Tan H; Zhang J; Zhao W; Chan MD; Zhou X
Med Phys; 2016 Nov; 43(11):5889. PubMed ID: 27806598
[TBL] [Abstract][Full Text] [Related]
35. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
36. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury.
Elias AE; Carlos RC; Smith EA; Frechtling D; George B; Maly P; Sundgren PC
Acad Radiol; 2011 Sep; 18(9):1101-8. PubMed ID: 21820634
[TBL] [Abstract][Full Text] [Related]
37. Interval Change in Diffusion and Perfusion MRI Parameters for the Assessment of Pseudoprogression in Cerebral Metastases Treated With Stereotactic Radiation.
Knitter JR; Erly WK; Stea BD; Lemole GM; Germano IM; Doshi AH; Nael K
AJR Am J Roentgenol; 2018 Jul; 211(1):168-175. PubMed ID: 29708785
[TBL] [Abstract][Full Text] [Related]
38. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence.
Radbruch A; Fladt J; Kickingereder P; Wiestler B; Nowosielski M; Bäumer P; Schlemmer HP; Wick A; Heiland S; Wick W; Bendszus M
Neuro Oncol; 2015 Jan; 17(1):151-9. PubMed ID: 25038253
[TBL] [Abstract][Full Text] [Related]
39. Distinguishing Progression from Pseudoprogression in Glioblastoma Using
Nabavizadeh A; Bagley SJ; Doot RK; Ware JB; Young AJ; Ghodasara S; Zhao C; Anderson H; Schubert E; Carpenter EL; Till J; Henderson F; Pantel AR; Chen HI; Lee JYK; Amankulor NM; O'Rourke DM; Desai A; Nasrallah MP; Brem S
J Nucl Med; 2023 Jun; 64(6):852-858. PubMed ID: 36549916
[TBL] [Abstract][Full Text] [Related]
40. The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
Bulik M; Kazda T; Slampa P; Jancalek R
Biomed Res Int; 2015; 2015():641023. PubMed ID: 26448943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
